


# Thrombolytic therapy

- Summary. (Slides 2,3 and 4)
- MCQS. (slide 5)
- SAQ. (slide 6)







-

# Thrombolytic agents:

Drugs used to lyse already formed blood clot in clinical sittings where ischemia may be fatal.

# Mechanism of action of thrombolytic agents:

They have common mechanism of action by stimulating activation of plasminogen via converting plasminogen to "pro-enzyme" to plasmin "active enzyme" which leads to lysis of the insoluble fibrin into soluble derivatives.

# Types of thrombolytic agents:

Thrombolytic agents produces there action by activation of plasminogen. How ever, the activation of free plasminogen could lead to a serious side effects like bleeding and to prevent that we had to make a new drugs that is fibrin specific which activate plasminogen located in an already formed colt with a little affinity to the free plasminogen.

# Types of thrombolytic agents

# Fibrin specific

Activate mainly plasminogen located on the surface of the clot.

This group includes:

- Alteplase.
- Reteplase.
- Tenecteplase.

# Non-fibrin specific

Activate plasminogen in general with no specificity to either free plasminogen or the plasminogen located on the surface of a clot. This group includes:

- Streptokinase.
- Anistreplase.
- Urokinase.



# Non-fibrin specific agents

	Streptokinase	Anistreplase	Urokinase
Mechanism of action	Acts indirectly by forming streptokinase-plasminogen complex which then convert plasminogen to active plasmin.	It is an anisoylated plasminogen- streptokinase complex and it's a prodrug.	An human enzyme that is secreted form the kidney w is a direct plasminogen activator.
Pharmacokinetics and uses	<ul> <li>T ½ less than 20 min.</li> <li>Given as IV infusion.</li> <li>Used in arterial and venous thrombosis.</li> </ul>	<ul> <li>Longer duration of action.</li> <li>Greater clot selectivity.</li> <li>Given as IV bolus.</li> </ul>	<ul> <li>Elimination t ½ 12 to 20 min.</li> <li>Given IV infeusion.</li> <li>Used in acute massive pulmonary embolism.</li> </ul>
Side effects and contraindications	<ul> <li>Antigenicity.</li> <li>Allergic reaction.</li> <li>Bleeding</li> <li>Should not be given to</li> <li>Patient with resent streptococcus infection.</li> <li>Previous administration of the drug.</li> </ul>		<ul> <li>Minimal fibrin selectivity.</li> <li>Expensive and to used nowadays.</li> </ul>

Fibrin s

# Alteplase.

- Is a recombinant form of human t-PA.
- Has a very short duration of action "5 min".
- It's usually administered as an intravenous • bolus followed by an infusion. (60 mg IV bolus then 40 mg infusion over 2 hours).
- Used in:
  - Elevation of ST segment. •
  - Pulmonary embolism

- A variant of recombination
- It has longer duration of lacksquare
- Has enhanced fibrin spe •
- Given as 2 IV bolus injec
- Used in: ●
  - Elevation of ST seg
  - Pulmonary embol •

brin specific agents	
Reteplase	tenecteplase
mbinant t-PA. tion of action (15 min). rin specificity. s injections of 10 U each. (NO INFUSION)	<ul> <li>Another modified human t-PA.</li> <li>Prepared by recombinant DNA technology.</li> <li>Has t ½ of more than 30 min.</li> <li>Can be administered as a single IV bolus.</li> <li>More fibrin-specific with longer duration of</li> </ul>
<sup>5</sup> ST segment. embolism.	<ul> <li><u>action.</u></li> <li>Approved only to be used in acute myocardia infarction.</li> </ul>

which
al

# **Fibrinolytic Inhibitors (Antiplasmins)**

inhibit plasminogen activation and thus inhibit fibrinolysis and promote clot stabilization.

Drug	Aminocaproic Acid & tranexamic acid	
Mechanism	Competitive Inhibition of Plasminogen Activation.	
Administration	Orally.	
Uses	<ul> <li>Antidote f</li> </ul>	۹ر ص

These drugs work like antidotes for fibrinolytic drugs. Similar to Protamine (Antidote of the anticoagulant, heparin) or Vitamin K (Antidote of the oral anticoagulant warfarin).



# Aprotinin

# inhibits fibrinolysis by blocking the action of plasmin (Plasmin antagonist).

Orally or IV.

djuvant therapy in hemophilia.

- Postsurgical bleeding.
- or Fibrinolytic therapy-induced bleeding.






- Which id considered "fibrin selective" because it rapidly activate plasminogen that is bound to fibrin.
   Which one of the following has the longest duration of action?
   A. Urokinase.
  - A. Alteplase.
  - B. Fondaparinux.
  - C. Streptokinase.
  - D. Urokinase.
- 2. which of the following drugs is approved to be used in ST segment elevation with longer half-life?
  - A. Urokinase.
  - B. Alteplase.
  - C. Reteplase.
  - D. Anistreplase.
- 3. Streptokinase is a bacterial protein that is produced by:
  - A. Alpha-hemolytic streptococci.
  - B. Beta-hemolytic streptococci.
  - C. Staphylococcus aureus.
  - D. Escherichia coli.
- 4. Which is can't be used in patient with previous streptococcal infection?
  - A. Streptokinase.
  - B. Anistreplase.
  - C. Urokinase.
  - D. A and B.



# MCQs

- B. Anistreplase.
- C. Streptokinase.
- D. Tenecteplase.
- 5. Which of the following is a prodrug?
  - A. Urokinase.
  - B. Streptokinase.
  - C. Tenecteplase.
  - D. Anistreplase.
- 6. Which of the following is a relative contraindication for using thrombolytic agents?
  - A. Major surgery within 2 weeks.
  - B. Pulmonary fat embolism after multiple fraction.
  - C. Severe uncontrolled hypertension.
  - D. Active internal bleeding.
- 7. Which one of the following can be used as antidote for warfarin?
  - A. Aminocarpoic acid.
  - B. Aprotinin.
  - C. Protamine.
  - D. Vitamin K.





A 66-year-old man presents to the emergency room with 10/10 substernal chest pain, and pressure radiating into his jaw that has been occurring for the last six hours. He has a history of coronary artery disease, hypertension, diabetes, and dyslipidemia. After examination the ECG shows ST segment elevation. They diagnosed him with ST segment elevation Myocardial infarction.

## Q1: What is the drug of choice in this situation?

All tissue plasminogen activator can be used specially tenecteplase because it's approved to be used in such an acute situation

## Q2: What is the mechanism of action of this drug?

It's a tissue plasminogen activator which is fibrin specific that works by activating plasminogen bound to the clot surface.

## Q3: What is the time frame should this drugs be administered in and why?

Because the clot get resistant to the thrombolytic agents with aging and there will be a massive tissue damage which that can't be reversible with the reperfusion.

## Q4: List 3 absolute contraindication of thrombolytic agents.

Intracranial hemorrhage

4 hours


- Major surgery with 2 weeks.
- Active internal bleeding.

# Q5: Write ONE major advantage of fibrin specific thrombolytic over non-fibrin specific agents.

Less affinity to systemic circulating plasminogen which makes the risk of bleeding much less











## Done by:

Abdulrahman Thekry

**Revised by:** 

Ghadah Almuhana

Ξ